Long-term safety and efficacy of daily recombinant human growth hormone treatment in Japanese short children born small for gestational age: final report from an open and multi-center study-Reference-Cited by-同舟云学术

Long-term safety and efficacy of daily recombinant human growth hormone treatment in Japanese short children born small for gestational age: final report from an open and multi-center study

Published:2018 Issue:3 Volume:27 Page:145-157
ISSN:0918-5739
Container-title:Clinical Pediatric Endocrinology
language:en
Short-container-title:Clin Pediatr Endocrinol

Author:

Tanaka Toshiaki¹,Yokoya Susumu²,Hoshino Yuko³,Hiro Shintaro⁴,Ohki Nobuhiko⁵

Affiliation:

1. Tanaka Growth Clinic, Tokyo, Japan

2. Thyroid and Endocrine Center, Fukushima Medical University, Fukushima, Japan

3. Clinical Research, Development Japan, Pfizer Japan Inc., Tokyo, Japan

4. Clinical Statistics, Development Japan, Pfizer Japan Inc., Tokyo, Japan

5. Medical Affairs, Rare Disease, Pfizer Japan Inc., Tokyo, Japan

Publisher

Japanese Society for Pediatric Endocrinology

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Pediatrics, Perinatology, and Child Health

Link

https://www.jstage.jst.go.jp/article/cpe/27/3/27_2018-0003/_pdf

Reference25 articles.

1. 1. Lee, PA, Chernausek, SD, Hokken-Koelega, AC, Czernichow, P, International Small for Gestational Age Advisory Board. International Small for Gestational Age Advisory Board consensus development conference statement: management of short children born small for gestational age, April 24-October 1, 2001. Pediatrics 2003;111: 1253–61.

2. 2. Clayton, PE, Cianfarani, S, Czernichow, P, Johannsson, G, Rapaport, R, Rogol, A. Management of the child born small for gestational age through to adulthood: a consensus statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society. J Clin Endocrinol Metab 2007;92: 804–10.

3. 3. The Japanese Society for Pediatric Endocrinology, Japan Society for Premature and Newborn Medicine. Guideline for GH treatment in SGA short children. Nippon Shonika Gakkai Zasshi 2007;111: 641–6 (in Japanese).

4. 4. Tanaka, T, Fujieda, K, Yokoya, S, Seino, Y, Tada, H, Mishina, J. Efficacy and safety of growth hormone treatment in children born small for gestational age in Japan. J Pediatr Endocrinol Metab 2008;21: 423–31.

5. 5. Tanaka, T, Yokoya, S, Fujieda, K, Seino, Y, Tada, H, Mishina, J, et al. Efficacy and safety of up to 8 years of long-term growth hormone treatment in short children born small for gestational age in Japan: analysis of the subpopulation according to the Japanese guideline. Clin Pediatr Endocrinol 2012;21: 57–68.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. Auxological and metabolic effects of long-term treatment with recombinant growth hormone in children born small for gestational age: a retrospective study;Endocrine;2024-01-12

3. Intact FGF23 concentration in healthy infants, children, and adolescents, and diagnostic usefulness in patients with X-linked hypophosphatemic rickets;Journal of Endocrinological Investigation;2023-11-22

4. Long-Term Efficacy and Safety of Recombinant Human Growth Hormone in Children Born Small for Gestational Age;Hormone and Metabolic Research;2023-09

5. Growth hormone treatment in small for gestational age children. Experience in one center;Archivos Argentinos de Pediatria;2023-08-01